Multiple screening for fetal down's syndrome with the classic triple test, dimeric inhibin A and ultrasound

Gynecologic and Obstetric Investigation

Volumn 49, Issue 4, 2000, Pages 221-226

  Debieve F ^a,b   Bouckaert, A ^a   Hubinont, C ^a   Thomas, K ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Faculty of Medicine   (Belgium)

Author keywords

Down's syndrome screening; Inhibin A; Ultrasound

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; INHIBIN A; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOWN SYNDROME; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR; GESTATIONAL AGE; HUMAN; LABORATORY DIAGNOSIS; MATERNAL SERUM; MULTIVARIATE ANALYSIS; NECK MUSCLE; PRENATAL SCREENING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SECOND TRIMESTER PREGNANCY;

EID: 0343183932     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010263     Document Type: Article

References (25)

1. Wald NJ, Kennard A, Hackshow A, McGuire A: Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246.
2. Ross HL, Elias S: Maternal serum screening for fetal genetic disorders. Obstet Gynecol Clin North Am 1997;24:33-47.
3. Cuckle HS, Wald NJ, Linderbaum RH: Maternal serum alpha-fetoprotein measurement: A screening test for Down syndrome. Lancet 1984;i:926-929.
4. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ: Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988;94:330-333.
5. Bogart MH, Pandian MR, Jones OW: Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623-630.
6. Reynolds TM, Penney MD: The mathematical basis of multivariate risk screening with special reference to screening for Down's syndrome-associated pregnancy. Ann Clin Biochem 1990; 27:452-458.
7. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkiners A, Canick JA, et al: Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992; 327:588-593.
8. Leschot NJ, Verjaal M, Treffers PE: Risk of midtrimester amniocentesis: Assessment in 3,000 pregnancies. Br J Obstet Gynaecol 1985; 92:804-807.
9. Wenstrom KD, Owen J, Chu DC, Boots L: Elevated second-trimester dimeric inhibin A levels identify Down syndrome pregnancies. Am J Obstet Gynecol 1997;177:992-996.
10. Cuckle HS, Holding S, Jones R, Groome NP, Wallace EM: Combining inhibin A with existing second-trimester markers in maternal serum screening tor Down's syndrome. Prenat Diagn 1996;16:1095-1100.
11. Spencer K, Wallace EM, Ritoe S: Second-trimester dimeric inhibin A in Down's syndrome screening. Prenat Diagn 1996;16:1101-1110.
12. Nyberg DA, Luthy DA, Resta RG, Nyberg BC, Williams MA: Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: Description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998;12:8-14.
13. Verdin SM, Economides DL: The role of ultrasonographic markers for trisomy-21 in women with positive serum biochemistry. Br J Obstet Gynaecol 1998;105:63-67.
14. Groome NP, O'Brien M: Preparation and applications of monoclonal antibodies to inhibin and its subunits. Front Endocrinol 1994;3:33-44.
15. Groome NP, Illingworth PJ, O'Brien M, Cook I, Ganesan TS, Baird DT, et al: Detection of dimeric inhibin throughout the human menstrual cycle. Clin Endocrinol 1994;40:717-723.
16. Cuckle HS, Wald NJ, Thompson SG: Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387-402.
17. Wald NJ, Watt HC: Serum markers for Down's syndrome in relation to number of previous births and maternal age. Prenat Diagn 1996;16: 699-703.
18. Wenstrom KD, Owen J, Chu DC, Boots L: α-Fetoprotein, free β-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome. Am J Obstet Gynecol 1997;177:987-991.
19. Wald NJ, Densem JW, Georges L, Mattukrishna S, Knight PG: Prenatal screening for Down's syndrome using inhibin A as a serum marker (published erratum appears in Prenat Diagn 1997;17:285-290). Prenat Diagn 1996; 16:143-153.
20. Spencer K, Wood PJ, Anthony FW: Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993; 30:219-220.
21. Macri JN, Kasturi RV, Krantz DA, Cook EJ, Sundedi SG, Larsen JW, et al: Maternal serum Down syndrome screening: Unconjugated estriol is not useful. Am J Obstet Gynecol 1990; 162:672-673.
22. Bahado-Singh RO, Deren O, Tan A, D'Ancona RL, Hunter D, Copel JA, et al: Ultrasonographically adjusted midtrimester risk of trisomy-21 and significant chromosomal defects in advanced maternal age. Am J Obstet Gynecol 1996;175:1563-1568.
23. Borrell A, Costa D, Ojuel J, Martinez JM, Seres A, Margarit E, et al: Limited effectiveness of femur and humerus shortening as markers of Down syndrome in early midtrimester fetuses. Fetal Diagn Ther 1997;12:156-162.
24. Wise J: Nuchal test detects 80% of Down's syndrome pregnancies. BMJ 1998;317:368.
25. Wald NJ, George L, Smith D, Dersem JW, Petterson K: Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996;103:407-412.